Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LON D LYNN

Allopathic & Osteopathic Physicians Family Medicine

NPI
1497898282
CMS profile
204601
Location
TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$1,059.37

59 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,031.59 57
Education $27.78 2

By paying entity

PY2021 · entire year · sorted by reported total

Page 1 of 2; records 1–50 of 59 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LON D LYNN

NPI 1497898282 · CMS profile ID 204601

Allopathic & Osteopathic Physicians / Family Medicine

TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 59 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1497898282?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LON D LYNN, NPI 1497898282, CMS profile ID 204601. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 59 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1497898282?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). LON D LYNN, NPI 1497898282, CMS profile ID 204601. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 59 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1497898282?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
LON D LYNN, NPI 1497898282, CMS profile ID 204601, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 59 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1497898282?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

59 matching records · $1,059.37 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 59 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 59.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amneal Pharmaceuticals LLC $13.4812/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829667317 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $24.4212/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763716532 CMS
Smith+Nephew, Inc. $59.5812/09/2021 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 843159417 CMS
Eisai Inc. $18.5912/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845775529 CMS
AstraZeneca Pharmaceuticals LP $15.0211/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829654089 CMS
AstraZeneca Pharmaceuticals LP $16.3311/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829776629 CMS
Novo Nordisk Inc $24.1711/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811094405 CMS
Endo Pharmaceuticals Inc. $16.3210/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 828700153 CMS
AstraZeneca Pharmaceuticals LP $13.3710/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829548257 CMS
Merck Sharp & Dohme Corporation $12.9610/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848445245 CMS
Genentech USA, Inc. $14.9910/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835942209 CMS
Abbott Laboratories $18.4510/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815725597 CMS
Bayer HealthCare Pharmaceuticals Inc. $19.0110/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789035181 CMS
AstraZeneca Pharmaceuticals LP $14.0409/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829351817 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $20.7809/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763716534 CMS
Amgen Inc. $13.8909/21/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826534999 CMS
Amneal Pharmaceuticals LLC $11.6709/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829667311 CMS
DEXCOM, INC. $16.9209/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845286859 CMS
Novo Nordisk Inc $19.5209/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811133699 CMS
Abbott Laboratories $22.4608/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833732605 CMS
Bayer HealthCare Pharmaceuticals Inc. $12.2408/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789167369 CMS
Lilly USA, LLC $22.4708/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818660655 CMS
Merck Sharp & Dohme Corporation $14.8308/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848467299 CMS
Amgen Inc. $18.2708/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825560071 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $31.6607/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763716536 CMS
AstraZeneca Pharmaceuticals LP $13.6007/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829901891 CMS
Novo Nordisk Inc $16.4507/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810976691 CMS
Novo Nordisk Inc $2.5206/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810897871 CMS
Novo Nordisk Inc $19.1306/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810897879 CMS
AstraZeneca Pharmaceuticals LP $14.6006/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829897633 CMS
AstraZeneca Pharmaceuticals LP $12.1806/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829938303 CMS
SANOFI-AVENTIS U.S. LLC $20.5506/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843408675 CMS
AstraZeneca Pharmaceuticals LP $13.9506/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829329589 CMS
AstraZeneca Pharmaceuticals LP $12.4006/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829395613 CMS
Amgen Inc. $14.8506/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825560067 CMS
DEXCOM, INC. $18.4205/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845286857 CMS
Novo Nordisk Inc $24.1105/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810937589 CMS
Lilly USA, LLC $11.5505/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818596861 CMS
Merck Sharp & Dohme Corporation $11.2004/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848597345 CMS
Amneal Pharmaceuticals LLC $18.7804/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829667307 CMS
AstraZeneca Pharmaceuticals LP $16.5204/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830073867 CMS
Novo Nordisk Inc $17.5704/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811094399 CMS
SANOFI-AVENTIS U.S. LLC $20.9804/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843408643 CMS
Amgen Inc. $13.5004/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825560063 CMS
Amgen Inc. $13.8904/14/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826534997 CMS
Novo Nordisk Inc $20.2203/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811173081 CMS
SANOFI-AVENTIS U.S. LLC $16.8603/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843408607 CMS
Radius Health, Inc. $23.2803/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830727017 CMS
AstraZeneca Pharmaceuticals LP $13.1802/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829485817 CMS
AstraZeneca Pharmaceuticals LP $13.6802/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829984441 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,623.35 59
PY2020 $4,240.58 60
PY2021 $1,059.37 59
PY2022 $317.77 13
PY2023 $770.34 4
PY2024 $2,741.69 24

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,774,310.43 131
PY2024 Recipient $1,401.65 10
PY2024 Principal investigator $1,886,016.65 154
PY2023 Recipient $1,734.07 2
PY2023 Principal investigator $1,613,093.87 174
PY2022 Recipient $7,938.00 2
PY2022 Principal investigator $1,203,947.96 117
PY2021 Recipient $1,793.52 3
PY2021 Principal investigator $874,519.06 78
PY2020 Principal investigator $706,623.45 80
PY2019 Recipient $1,208.55 9
PY2019 Principal investigator $596,855.42 115

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

176 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $18,988.94 12/31/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Randomized, Double-Blind, 12-Week (with an Extension to 52 Weeks in a subset of Participants), Multi-Center Study to Assess the Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) No dispute reported 06/30/2026 991127101
Principal investigator 1 AstraZeneca UK Limited $1,002.56 12/31/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 2 Multinational Randomized Double blind Parallel group 16 week Placebo controlled Study with a 36 week Extension to Investigate the Use of Benralizumab for Patients with Moderate to Severe Atopic Dermatitis Despite Treatment with Topical Medications No dispute reported 06/30/2026 991134581
Principal investigator 1 Averitas Pharma Inc. $1,913.40 12/19/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763677
Principal investigator 1 Eli Lilly and Company $14,000.00 12/18/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 3 RANDOMIZED OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) No dispute reported 06/30/2026 1038078383
Principal investigator 1 SANOFI US SERVICES INC. $6,925.00 12/18/2023 Non-covered Recipient Entity
Clinical Research Of West Florida
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1036001985
Principal investigator 1 Biogen, Inc. $23,304.45 12/14/2023 Non-covered Recipient Entity
Clinical Research Of West Florida
A Phase 2 Study of RTA 901 in Patients With Diabetic Peripheral Neuropathic Pain (CYPRESS) (CYPRESS) No dispute reported 06/30/2026 1012178101
Principal investigator 1 Averitas Pharma Inc. $862.20 12/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763675
Principal investigator 1 Averitas Pharma Inc. $2,059.20 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763673
Principal investigator 1 Averitas Pharma Inc. $5,582.70 11/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763671
Principal investigator 1 SANOFI US SERVICES INC. $6,450.00 11/20/2023 Non-covered Recipient Entity
Clinical Research Of West Florida
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1036001966
Principal investigator 1 Averitas Pharma Inc. $6,779.70 11/17/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763669
Principal investigator 1 ABBVIE INC. $2,500.00 11/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 998407309
Principal investigator 1 ABBVIE INC. $5,030.80 11/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 998406479
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2.94 11/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059683209
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $4.90 11/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059684197
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $9.31 11/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059684969
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $7.84 11/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059685683
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $7.35 11/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059686605
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $6.86 11/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059686981
Principal investigator 1 Mylan Specialty L.P. $7,479.25 11/03/2023 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) No dispute reported 06/30/2026 1038208571
Principal investigator 1 Averitas Pharma Inc. $1,500.00 10/25/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763659
Principal investigator 1 Averitas Pharma Inc. $2,000.00 10/25/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763661
Principal investigator 1 Averitas Pharma Inc. $3,663.00 10/25/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763663
Principal investigator 1 Averitas Pharma Inc. $4,500.00 10/25/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763665
Principal investigator 1 Averitas Pharma Inc. $1,500.00 10/25/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763667
Principal investigator 1 SANOFI US SERVICES INC. $18,950.00 10/23/2023 Non-covered Recipient Entity
Clinical Research Of West Florida
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1036001927
Principal investigator 1 ABBVIE INC. $280.00 10/17/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 998404331
Principal investigator 1 Averitas Pharma Inc. $1,603.80 10/17/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763657
Principal investigator 1 ABBVIE INC. $1,542.45 10/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 998403897
Principal investigator 1 Eli Lilly and Company $3,155.50 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 3 RANDOMIZED OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) No dispute reported 06/30/2026 1038083041
Principal investigator 1 ABBVIE INC. $3,095.75 10/04/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 998401759
Principal investigator 1 Averitas Pharma Inc. $1,913.40 10/03/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763655
Principal investigator 1 UCB SA $756.00 10/02/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF DAPIROLIZUMAB PEGOL TREATMENT IN STUDY PARTICIPANTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1059101303
Principal investigator 1 Averitas Pharma Inc. $2,302.20 09/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763653
Principal investigator 1 SANOFI US SERVICES INC. $5,300.00 09/18/2023 Non-covered Recipient Entity
Clinical Research Of West Florida
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1036001917
Principal investigator 1 ABBVIE INC. $2,280.25 09/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 998399365
Principal investigator 1 ABBVIE INC. $1,822.50 09/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 998399367
Principal investigator 1 Averitas Pharma Inc. $2,642.40 09/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763651
Principal investigator 1 Averitas Pharma Inc. $5,904.90 09/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763649
Principal investigator 1 Mylan Specialty L.P. $11,155.25 09/01/2023 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) No dispute reported 06/30/2026 1038208565
Principal investigator 1 GlaxoSmithKline, LLC. $327.90 08/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 1006258741
Principal investigator 1 SANOFI US SERVICES INC. $550.00 08/28/2023 Non-covered Recipient Entity
Clinical Research Of West Florida
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1036001905
Principal investigator 1 ABBVIE INC. $1,105.00 08/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 998396583
Principal investigator 1 AstraZeneca UK Limited $5,685.68 08/23/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 2b Multinational Randomised Double-blind Parallelgroup 24-week Placebo-controlled Study with 28-week Extension to Investigate the Use of Benralizumab in Patients with Moderate to Severe Chronic Spontaneous Urticaria No dispute reported 06/30/2026 991137135
Principal investigator 1 Averitas Pharma Inc. $3,353.40 08/18/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763647
Principal investigator 1 ABBVIE INC. $5,872.50 08/15/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 998395457
Principal investigator 1 ABBVIE INC. $323.25 08/10/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 998394687
Principal investigator 1 Averitas Pharma Inc. $12,276.00 08/10/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763645
Principal investigator 1 Novartis Pharmaceuticals Corporation $122,482.89 07/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1017200863
Principal investigator 1 SANOFI US SERVICES INC. $1,100.00 07/24/2023 Non-covered Recipient Entity
Clinical Research Of West Florida
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1036001885
Principal investigator 1 ABBVIE INC. $4,844.80 07/20/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 998391971
Principal investigator 1 Averitas Pharma Inc. $3,663.00 07/18/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763643
Principal investigator 1 ABBVIE INC. $6,311.05 07/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 998391335
Principal investigator 3 UCB SA $26,822.00 07/12/2023 Non-covered Recipient Entity
Clinical Research Of West Florida
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF DAPIROLIZUMAB PEGOL TREATMENT IN STUDY PARTICIPANTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1059101177
Principal investigator 1 ABBVIE INC. $2,497.50 07/11/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 998390097
Principal investigator 1 ABBVIE INC. $952.00 07/11/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 998390287
Principal investigator 1 ABBVIE INC. $1,542.45 07/11/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 998390289
Principal investigator 1 Averitas Pharma Inc. $1,603.80 07/11/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763641
Principal investigator 1 Eli Lilly and Company $2,686.26 07/11/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) No dispute reported 06/30/2026 1038101323
Principal investigator 1 Averitas Pharma Inc. $3,906.00 07/04/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763637
Principal investigator 1 Averitas Pharma Inc. $1,749.60 07/04/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763639
Principal investigator 1 ABBVIE INC. $1,903.95 06/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 998387675
Principal investigator 1 Averitas Pharma Inc. $4,246.20 06/20/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763635
Principal investigator 1 Averitas Pharma Inc. $1,500.00 06/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763629
Principal investigator 1 Averitas Pharma Inc. $2,250.00 06/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763631
Principal investigator 1 Averitas Pharma Inc. $2,387.70 06/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763633
Principal investigator 1 ABBVIE INC. $10,249.03 06/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 998386007
Principal investigator 1 Averitas Pharma Inc. $1,603.80 06/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763627
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $314.28 06/02/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059680923
Principal investigator 1 Mylan Specialty L.P. $19,557.50 06/01/2023 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) No dispute reported 06/30/2026 1038208577
Principal investigator 1 Averitas Pharma Inc. $1,913.40 05/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763625
Principal investigator 1 SANOFI US SERVICES INC. $550.00 05/25/2023 Non-covered Recipient Entity
Clinical Research Of West Florida
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1036001833
Principal investigator 1 ABBVIE INC. $2,550.00 05/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 998384321
Principal investigator 1 Averitas Pharma Inc. $1,603.80 05/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763623
Principal investigator 1 Averitas Pharma Inc. $135.00 05/19/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763619
Principal investigator 1 Averitas Pharma Inc. $2,652.75 05/19/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763621
Principal investigator 1 GlaxoSmithKline, LLC. $4,352.50 05/18/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 1006258735
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 05/18/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 1006258747
Principal investigator 1 ABBVIE INC. $5,569.25 05/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 998383433
Principal investigator 1 Averitas Pharma Inc. $3,353.40 05/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763617
Principal investigator 1 ABBVIE INC. $9,429.09 05/11/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 998382191
Principal investigator 1 Mylan Specialty L.P. $384.25 05/10/2023 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) No dispute reported 06/30/2026 1038208625
Principal investigator 1 Averitas Pharma Inc. $1,749.60 05/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763615
Principal investigator 1 Averitas Pharma Inc. $3,663.00 05/03/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763613
Principal investigator 1 Eli Lilly and Company $45,450.00 05/02/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 3 PARALLEL-DESIGN OPEN-LABEL RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 ADMINISTERED WEEKLY USING A FIXED DOSE ESCALATION COMPARED TO INSULIN GLARGINE IN INSULIN-NAIVE ADULTS WITH TYPE 2 DIABETES No dispute reported 06/30/2026 1038085127
Principal investigator 1 Averitas Pharma Inc. $1,603.80 04/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763611
Principal investigator 1 SANOFI US SERVICES INC. $9,700.00 04/24/2023 Non-covered Recipient Entity
Clinical Research Of West Florida
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1036001811
Principal investigator 1 Averitas Pharma Inc. $2,156.40 04/18/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763609
Principal investigator 1 ABBVIE INC. $1,542.45 04/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 998378161
Principal investigator 1 ABBVIE INC. $8,033.86 04/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 998378203
Principal investigator 1 SANOFI US SERVICES INC. $692.90 04/10/2023 Non-covered Recipient Entity
Clinical Research Of West Florida
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1036001803
Principal investigator 1 ABBVIE INC. $1,532.50 04/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 998376945
Principal investigator 1 Averitas Pharma Inc. $7,928.10 04/04/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763605
Principal investigator 1 Averitas Pharma Inc. $309.60 04/04/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763607
Principal investigator 1 Eli Lilly and Company $225,500.00 04/04/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1038076121
Principal investigator 1 Mylan Specialty L.P. $1,901.47 03/31/2023 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) No dispute reported 06/30/2026 1038208583
Principal investigator 1 Averitas Pharma Inc. $2,059.20 03/29/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763603
Principal investigator 1 Averitas Pharma Inc. $1,000.00 03/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763597
Principal investigator 1 Averitas Pharma Inc. $1,603.80 03/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763599
Principal investigator 1 SANOFI US SERVICES INC. $10,825.00 03/20/2023 Non-covered Recipient Entity
Clinical Research Of West Florida
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1036001775
Principal investigator 1 ABBVIE INC. $323.25 03/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 998374441
Principal investigator 1 ABBVIE INC. $1,778.15 03/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 998374687
Principal investigator 1 ABBVIE INC. $9,007.21 03/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 998374689
Principal investigator 1 SANOFI US SERVICES INC. $1,235.00 03/13/2023 Non-covered Recipient Entity
Clinical Research Of West Florida
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1036001765
Principal investigator 1 Averitas Pharma Inc. $4,451.75 03/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763585
Principal investigator 1 Averitas Pharma Inc. $1,215.00 03/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763587
Principal investigator 1 Averitas Pharma Inc. $4,725.00 03/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763589
Principal investigator 1 Averitas Pharma Inc. $405.00 03/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763595
Principal investigator 1 Mylan Specialty L.P. $11,960.02 03/08/2023 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) No dispute reported 06/30/2026 1038208643
Principal investigator 1 SANOFI US SERVICES INC. $4,000.00 03/06/2023 Non-covered Recipient Entity
Clinical Research Of West Florida
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1036001727
Principal investigator 1 SANOFI US SERVICES INC. $1,500.00 03/06/2023 Non-covered Recipient Entity
Clinical Research Of West Florida
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1036001745
Principal investigator 1 Averitas Pharma Inc. $309.60 02/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763583
Principal investigator 1 Eli Lilly and Company $1,323.72 02/23/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A MASTER PROTOCOL FOR A RANDOMIZED PLACEBO-CONTROLLED CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1038085117
Principal investigator 1 Averitas Pharma Inc. $2,500.00 02/22/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763577
Principal investigator 1 Averitas Pharma Inc. $2,250.00 02/22/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763579
Principal investigator 1 Averitas Pharma Inc. $1,913.40 02/22/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763581
Principal investigator 1 Averitas Pharma Inc. $2,156.40 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763575
Principal investigator 1 UCB SA $16,051.76 02/16/2023 Non-covered Recipient Entity
Clinical Research Of West Florida
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1059100381
Principal investigator 1 Mylan Specialty L.P. $15,089.74 02/15/2023 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) No dispute reported 06/30/2026 1038208607
Principal investigator 1 Eli Lilly and Company $40,000.00 02/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A MASTER PROTOCOL FOR A RANDOMIZED PLACEBO-CONTROLLED CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1038082065
Principal investigator 1 ABBVIE INC. $6,455.03 02/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 998369331
Principal investigator 1 ABBVIE INC. $1,293.00 02/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 998369333
Principal investigator 1 Averitas Pharma Inc. $1,749.60 02/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763571
Principal investigator 1 Averitas Pharma Inc. $5,250.00 02/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763573
Principal investigator 1 AstraZeneca Pharmaceuticals LP $40,423.26 02/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase IIa Randomised, Double Blind, Placebo Controlled, Parallel Arm, Multi-Centre Study to Evaluate the Efficacy and Safety of AZD4831, for 12-24 Weeks, in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 991131195
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $164.80 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059678667
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $144.20 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059678783
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $154.50 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059678861
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $103.00 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059678985
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $195.70 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059679007
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $61.80 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059679097
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $6.00 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059679213
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $4.80 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059679335
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $4.20 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059679465
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $4.50 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059679549
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3.00 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059679701
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $5.70 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059679725
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3.00 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059679831
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.80 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059679849
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.96 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059679963
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $27.98 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059680147
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $38.80 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059680241
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $6.30 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059680443
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $5.40 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059680531
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $6.30 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059680591
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059680687
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $8.10 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059680711
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $5.40 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059680791
Principal investigator 1 ABBVIE INC. $5,000.00 02/02/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 998368505
Principal investigator 1 Averitas Pharma Inc. $5,995.80 02/02/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763569
Principal investigator 1 AstraZeneca UK Limited $6,052.57 02/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 2 Multinational Randomized Double blind Parallel group 16 week Placebo controlled Study with a 36 week Extension to Investigate the Use of Benralizumab for Patients with Moderate to Severe Atopic Dermatitis Despite Treatment with Topical Medications No dispute reported 06/30/2026 991137587
Recipient Eli Lilly and Company $298.02 01/31/2023 Covered Recipient Physician EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO AFTER AN INTENSIVE LIFESTYLE PROGRAM IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-3) No dispute reported 06/30/2026 1038052267
Principal investigator 1 Eli Lilly and Company $2,546.87 01/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A MULTICENTER RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PARALLEL-GROUP TWO-ARM PHASE 2 CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3361237 AS A TREATMENT FOR ADULTS WITH AT LEAST MODERATELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1038079199
Principal investigator 1 Eli Lilly and Company $4,876.45 01/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 3 PARALLEL-DESIGN OPEN-LABEL RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 ADMINISTERED WEEKLY USING A FIXED DOSE ESCALATION COMPARED TO INSULIN GLARGINE IN INSULIN-NAIVE ADULTS WITH TYPE 2 DIABETES No dispute reported 06/30/2026 1038082933
Principal investigator 1 Eli Lilly and Company $153.14 01/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO AFTER AN INTENSIVE LIFESTYLE PROGRAM IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-3) No dispute reported 06/30/2026 1038083011
Principal investigator 1 Novartis Pharmaceuticals Corporation $15,544.00 01/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1017209911
Principal investigator 1 Averitas Pharma Inc. $4,446.90 01/25/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763567
Principal investigator 1 Averitas Pharma Inc. $5,103.00 01/20/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763565
Principal investigator 1 AstraZeneca Pharmaceuticals LP $328,171.76 01/18/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Randomized, Double-Blind, 12-Week (with an Extension to 52 Weeks in a subset of Participants), Multi-Center Study to Assess the Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) No dispute reported 06/30/2026 991131295
Principal investigator 1 ABBVIE INC. $3,422.90 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 998365585
Principal investigator 1 ABBVIE INC. $11,200.29 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 998365609
Principal investigator 1 Averitas Pharma Inc. $965.00 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763559
Principal investigator 1 Averitas Pharma Inc. $338.00 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763561
Principal investigator 1 Averitas Pharma Inc. $135.00 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763563
Principal investigator 1 Averitas Pharma Inc. $862.20 01/10/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763557
Recipient Eli Lilly and Company $1,436.05 01/10/2023 Covered Recipient Physician A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) No dispute reported 06/30/2026 1038053677
Principal investigator 1 Eli Lilly and Company $26,994.00 01/10/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO AFTER AN INTENSIVE LIFESTYLE PROGRAM IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-3) No dispute reported 06/30/2026 1038082921
Principal investigator 1 Eli Lilly and Company $4,195.22 01/10/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1038083031
Principal investigator 1 ABBVIE INC. $9,086.33 01/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 998364475
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $837.00 01/09/2023 Non-covered Recipient Entity
Clinical Research Of West Florida - Tampa
Phase 2 CD (Primary represents Induction) - A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate to Severe Crohns Disease No dispute reported 06/30/2026 1027485789
Principal investigator 1 Averitas Pharma Inc. $309.60 01/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763553
Principal investigator 1 Averitas Pharma Inc. $4,720.50 01/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1058763555
Principal investigator 1 ABBVIE INC. $5,759.00 01/04/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 998363643
Principal investigator 1 Eli Lilly and Company $32,075.00 01/03/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A MULTICENTER RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PARALLEL-GROUP TWO-ARM PHASE 2 CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3361237 AS A TREATMENT FOR ADULTS WITH AT LEAST MODERATELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1038079525
Principal investigator 1 Eli Lilly and Company $39,522.00 01/03/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) No dispute reported 06/30/2026 1038082087
Principal investigator 1 Novartis Pharmaceuticals Corporation $122,703.15 01/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1017202429